摘要：Discusses the current state of syndromic surveillance using inpatient and ambulatory clinical data in the United States and the potential utility of the data. The Meaningful Use Stages 2 and 3 regulations incentivize the use of these data sources. Existing systems effectively perform a range of activities from influenza-like illness surveillance to heart disease risk factor surveillance. With further development, ambulatory and inpatient data could become an integral part of syndromic surveillance practice.
